Hello everyone. I'm new here -- drawn to the board by discussion of recent insider buys. Looking at the company, I'm unclear as to what makes this stock a buy here. Why did SNTA push forward with Phase III Ganetespib trial when the Phase II trial didn't show impressive results? Would love to hear thoughts. (Do please note, I come here hoping for some info, not bashing/hyping)
Thanks so much for the reply Dr. V.
From what I understand, the median survival on Ganetespib/docetaxel was 9.8 months vs. 7.4 on docetaxel alone. That doesn't seem to me to be statistically significant. (And did the investing world not clearly concur?) I don't have an agenda here. I'm just curious what you and others are hoping that the phase iii trial and more near future will hold.